Amphastar Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AMPH and other ETFs, options, and stocks.

About AMPH

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredients. It operates through Pharmaceutical Products segment. 

CEO
Yong Feng Zhang
CEOYong Feng Zhang
Employees
1,976
Employees1,976
Headquarters
Rancho Cucamonga, California
HeadquartersRancho Cucamonga, California
Founded
1996
Founded1996
Employees
1,976
Employees1,976

AMPH Key Statistics

Market cap
1.22B
Market cap1.22B
Price-Earnings ratio
13.13
Price-Earnings ratio13.13
Dividend yield
—
Dividend yield—
Average volume
578.07K
Average volume578.07K
High today
$29.30
High today$29.30
Low today
$28.51
Low today$28.51
Open price
$28.87
Open price$28.87
Volume
485.36K
Volume485.36K
52 Week high
$31.00
52 Week high$31.00
52 Week low
$16.65
52 Week low$16.65

Stock Snapshot

The current Amphastar Pharmaceuticals(AMPH) stock price is $28.60, with a market capitalization of 1.22B. The stock trades at a price-to-earnings (P/E) ratio of 13.13.

On 2026-11-11, Amphastar Pharmaceuticals(AMPH) stock moved within a range of $28.51 to $29.30. With shares now at $28.60, the stock is trading +0.3% above its intraday low and -2.4% below the session's peak.

Trading activity shows a volume of 485.36K, compared to an average daily volume of 578.07K.

The stock's 52-week range extends from a low of $16.65 to a high of $31.00.

The stock's 52-week range extends from a low of $16.65 to a high of $31.00.

AMPH News

Simply Wall St 5d
How Investors Are Reacting To Amphastar Pharmaceuticals Strong Third Quarter Earnings

Amphastar Pharmaceuticals reported Q3 2026 results with sales of US$207.61 million and net income of US$37.76 million, alongside higher basic and diluted earnin...

How Investors Are Reacting To Amphastar Pharmaceuticals Strong Third Quarter Earnings
Simply Wall St 6d
Amphastar Pharmaceuticals On Q3 Results Faces An Overvalued Narrative

Amphastar Pharmaceuticals (AMPH) just put fresh Q3 2026 numbers on the table, with management reporting higher quarterly sales, net income, and earnings per sha...

Amphastar Pharmaceuticals On Q3 Results Faces An Overvalued Narrative

Analyst ratings

86%

of 7 ratings
Buy
0%
Hold
85.7%
Sell
14.3%

People also own

Based on the portfolios of people who own AMPH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.